Onconetix, Inc. settled with IQVIA for $150,000 regarding a terminated Master Services Agreement, resulting in a $0.9 million adjustment in accounts payable. Additionally, its subsidiary Proteomedix AG shared a study on LinkedIn about Proclarix's potential benefits in prostate cancer detection.